行情

MGNX

MGNX

MacroGenics
NASDAQ

实时行情|Nasdaq Last Sale

5.28
-0.02
-0.38%
交易中 12:38 04/02 EDT
开盘
5.29
昨收
5.30
最高
5.43
最低
5.15
成交量
13.09万
成交额
--
52周最高
19.80
52周最低
4.040
市值
2.59亿
市盈率(TTM)
-1.6650
分时
5日
1月
3月
1年
5年

分析师评级

14位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测MGNX价格均价为17.82,最高价位40.00,最低价为6.00。

EPS

MGNX 新闻

更多
  • 瑞幸就造假一事在内部发文:相关人员已停职并被接任
  • 新浪财经 · 19分钟前
  • “大空头”查诺斯:盘前回补了在瑞幸咖啡的空头头寸
  • 新浪美股 · 20分钟前
  • 英国央行新量化宽松计划将纳入价值120亿美元的企业债
  • 新浪美股 · 21分钟前
  • 美联储放松监管将赋予银行做市能力
  • 新浪美股 · 23分钟前

所属板块

生物技术和医学研究
+2.04%
制药与医学研究
+1.65%

热门股票

代码
价格
涨跌幅

MGNX 简况

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.
展开

微牛提供MacroGenics Inc(NASDAQ-MGNX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的MGNX股票新闻,以帮助您做出投资决策。